ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INDP vs CBIO // ENTERPRISE SCALE & MARKET CAP

Indaptus Therapeutics Inc. (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: INDP 2 — CBIO 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CBIO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDP VS. CBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INDP CBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.89% -13.86% +10.97 INDP /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — 1.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.36 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 CBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.2 46.1 +8.11 INDP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $513.0M $522.6M -$9.7M CBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INDP REV CBIO REV INDP GROSS % CBIO GROSS % INDP FCF CBIO FCF
FY 2025 $0 $10.8M — — -$14.8M -$72.5M
FY 2024 $0 $0 — — -$12.3M -$31.1M
FY 2023 $0 $0 — — -$13.4M -$34.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDP // BETA —
CBIO // BETA —